2 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Familial Partial Lipodystrophy: new trials by email Literature Review of Familial Partial Lipodystrophy trials Research Report on Familial Partial Lipodystrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) REGN4461, Matching Placebo - Familial Partial Lipodystrophy, Metabolic Abnormalities | Phase 2 | Terminated | Regeneron Pharmaceuticals | 20 | 2022-02-28 | 2025-10-16 |
| The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy volanesorsen, Placebo - Familial Partial Lipodystrophy | Phase 2 / Phase 3 | Terminated | Akcea Therapeutics | 40 | 2015-12-28 | 2021-10-18 |
Lipodystrophy, Familial Partial (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Laminopathies (2) · Lipid Metabolism Disorders (2) · Lipid Metabolism, Inborn Errors (2) · Lipodystrophy (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Skin Diseases (2) · Skin Diseases, Metabolic (2) · Skin and Connective Tissue Diseases (2)
ISIS 304801 (1)
Akcea Therapeutics (1) · Regeneron Pharmaceuticals (1)
United States (2) · Belgium (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Netherlands (1) · Russia (1) · Spain (1) · Turkey (Türkiye) (1)
2015 (1)